KI researchers receive the award for best scientific publication in the field of prostate cancer

I am very happy and honored with this award. It’s good that at the EU level you now see the great value of an improved diagnostic tool like Stockholm 3. By using Stockholm 3 before an MRI, you can reduce the number of men who go to an MRI, without missing out on major cancers. He says it saves vital resources Tobias NordstromAssociate Professor of Urology at Department of Clinical Sciences, Danderyd Hospital (KI DS), at Karolinska Institutet and chair of the STHLM3MR study.

In 2021, the results of the STHLM3 MR study were published in Oncology Lancet. A Lancet editorial called the study “an important step for smarter screening for prostate cancer.” The article also won first prize for Best Abstract of Oncology at the EAU Conference in 2021. In early 2022, it was awarded Henrik Grunbergresearcher in Department of Medical Epidemiology and BiostatisticsThe Cancer Foundation’s “Cancer Investigator 2022” award for her world-leading research that enables early detection of prostate cancer. Henrik Grönberg and his team, which includes Tobias Nordström, have for many years conducted research in the field of prostate cancer, leading to Stockholm 3, which has been successfully in clinical use since 2017.

Publications

“Prostate cancer screening using a combination of risk prediction, MRI, and targeted prostate biopsies: results from the STHLM3MRI population-based trial.Nordstrom, A. Desciati, M. Bergmann, M. Clements, M. Ali, M. Anerstedt, A. Glaesgen, S. Carlson, F. Gaderling, H. Grunberg, M. Ecklund. Oncology Lancetonline August 12, 2021, doi: 10.1016/S1470-2045 (21) 00348-X.

Cost-effectiveness of the Stockholm test-3 and magnetic resonance imaging in prostate cancer screening: a micro-simulated study.. S. Hao, E. Heintz, E. Östensson, A. Discacciati, F. Jäderling, H. Grönberg, M. Eklund, T. Nordström, M. Clements. European Urologyonline Jan 27, 2022, doi: 10.1016/j.eururo.2021.12.021.

More on the STHLM3 MRI Study

Prostate cancer screening was not offered in Sweden because current methods, PSA tests with tissue sampling, mean that a large number of harmless tumors are detected (overdiagnosed) and tissue samples are taken unnecessarily. The STHLM3 MRI Study is a randomized, population-based study with 12,750 men in the age range 50 to 74 years. In the study, the standard PSA test was compared with the Stockholm Test 3, in which both tests were used with a magnetic (MR) camera and guided tissue samples or with conventional tissue sampling. Compared to current standard methods, PSA and conventional tissue sampling, the Stockholm test and magnetic camera reduced overdiagnosis by 69 percent, while maintaining the detection of dangerous tumors.